Actually the FDA appear to be very accomodating for MSB as per a) attending MOA conferences and b) changing approval processes so 60 days is the thing to look at and c) pointing out that secondary end points are fine..... Its as if they are being schooled by MSB in fact..... to enable approval on a sound scientific basis and no loss of face for the FDA for not just Covid-19.
Where is Novartis?, page-115
-
- There are more pages in this discussion • 1,402 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
93.5¢ |
Change
0.020(2.19%) |
Mkt cap ! $1.067B | |||
| Open | High | Low | Value | Volume |
| 92.0¢ | 94.5¢ | 92.0¢ | $1.622M | 1.742M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 64563 | 93.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.0¢ | 204239 | 3 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |